# Risicostratificatie met geïntegreerde devicediagnostiek bij hartfalen

*geplaatst 2018-05-01 · Hartfalen · Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology · doi 10.1093/europace/eux206 · https://hartvaat.nl/2018/05/01/risicostratificatie-met-geintegreerde-devicediagnostiek-bij-hartfalen/*

Studie naar het gebruik van geïntegreerde devicediagnostiek voor risicostratificatie van cardiovasculaire en hartfalen-hospitalisaties.

## English: Risk stratification of cardiovascular and heart failure hospitalizations using integrated device diagnostics in patients with a cardiac resynchronization therapy defibrillator.

This study evaluated integrated CRT-D device diagnostics for risk stratification of cardiovascular hospitalizations, testing whether automated multi-parameter algorithms can provide actionable early warning of clinical deterioration.

## Abstract (original, from the publication)

AIMS: Cardiac resynchronization therapy defibrillators (CRT-D) are able to monitor various parameters that may be combined by an automatic algorithm to provide a heart failure risk status (HFRS). We sought to validate the HFRS for stratifying patient risk, evaluate its association with heart failure (HF) symptoms, and investigate its utility for triage of automatic alerts. METHODS AND RESULTS: Data from 722 patients included in the MORE-CARE trial were analysed in a post hoc analysis. A high HFRS was associated with a significantly increased risk of admission over the next 30 days with a relative risk for cardiovascular hospitalization (CVH) of 4.5 (95% CI: 3.1-6.6, P < 0.001), of HF hospitalization of 6.3 (95% CI: 3.9-10.2, P < 0.001) and of non-HF related CVH of 3.5 (95% CI: 2.0-6.9, P < 0.001). The negative predictive value of low or medium HFRS for these admissions was ≥98%. A high HFRS was associated with an increased risk of HF symptoms. Of all the automatic remote monitoring alerts generated during the study, only 10% had a high HFRS. CONCLUSION: The HFRS is able to risk-stratify CRT-D patients, which is potentially useful for managing automatic remote monitoring alerts, by focusing attention on the minority of high-risk patients. CLINICAL TRIAL REGISTRATION: The trial was registered at www.clinicaltrials.gov under number NCT00885677.

Auteurs: Haran Burri, Antoine da Costa, Aurelio Quesada, Renato Pietro Ricci, Stefano Favale, Nicolas Clementy, Gabriele Boscolo, Federico Segura Villalobos, Lorenza Mangoni di S Stefano, Vinod Sharma, Giuseppe Boriani

---
Bron: Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology, https://doi.org/10.1093/europace/eux206. Bijgewerkt 2026-07-03T18:38:38Z. Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies.